150 related articles for article (PubMed ID: 37335710)
1. Aberrant expression of UBE2C in endometrial cancer and its correlation to epithelial mesenchymal transition.
Zhang Y; Li X; Gong Y; Du D; Chen H; Liu L; Cheng Z
Medicine (Baltimore); 2023 May; 102(20):e33834. PubMed ID: 37335710
[TBL] [Abstract][Full Text] [Related]
2. The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance.
Gong Y; Wang D; Lin L; Dai J; Yu L
Medicine (Baltimore); 2019 Nov; 98(46):e17896. PubMed ID: 31725636
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance of ubiquitin-conjugating enzyme E2C, leucine-rich repeated-containing G protein-coupled receptor, WW domain-containing oxidoreductase, and vasculogenic mimicry in invasive breast carcinoma.
Shen R; Wu T; Huang P; Shao Q; Chen M
Medicine (Baltimore); 2019 Apr; 98(16):e15232. PubMed ID: 31008954
[TBL] [Abstract][Full Text] [Related]
4. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
5.
Liu Y; Zhao R; Chi S; Zhang W; Xiao C; Zhou X; Zhao Y; Wang H
Mol Cancer Res; 2020 Feb; 18(2):204-215. PubMed ID: 31662448
[TBL] [Abstract][Full Text] [Related]
6. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H
FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067
[TBL] [Abstract][Full Text] [Related]
7. The nuclear protein expression levels of SNAI1 and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer via the epithelial-mesenchymal transition pathway.
Chen Z; Li S; Huang K; Zhang Q; Wang J; Li X; Hu T; Wang S; Yang R; Jia Y; Sun H; Tang F; Zhou H; Shen J; Ma D; Wang S
Hum Pathol; 2013 Oct; 44(10):2097-105. PubMed ID: 23791009
[TBL] [Abstract][Full Text] [Related]
8. High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.
Shen Z; Jiang X; Zeng C; Zheng S; Luo B; Zeng Y; Ding R; Jiang H; He Q; Guo J; Jie W
BMC Cancer; 2013 Apr; 13():192. PubMed ID: 23587173
[TBL] [Abstract][Full Text] [Related]
9. MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis.
Chen M; Liu LX
Dig Dis Sci; 2020 Aug; 65(8):2442-2451. PubMed ID: 31679088
[TBL] [Abstract][Full Text] [Related]
10. UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy.
Morikawa T; Kawai T; Abe H; Kume H; Homma Y; Fukayama M
Int J Clin Exp Pathol; 2013; 6(7):1367-74. PubMed ID: 23826418
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
Kariri Y; Toss MS; Alsaleem M; Elsharawy KA; Joseph C; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2022 Apr; 192(3):529-539. PubMed ID: 35124721
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.
Li R; Pang XF; Huang ZG; Yang LH; Peng ZG; Ma J; He RQ
BMC Cancer; 2021 Sep; 21(1):996. PubMed ID: 34488675
[TBL] [Abstract][Full Text] [Related]
13. Cyr61/CCN1 overexpression induces epithelial-mesenchymal transition leading to laryngeal tumor invasion and metastasis and poor prognosis.
Liu Y; Zhou YD; Xiao YL; Li MH; Wang Y; Kan X; Li QY; Lu JG; Jin DJ
Asian Pac J Cancer Prev; 2015; 16(7):2659-64. PubMed ID: 25854342
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients.
Zhang HQ; Zhao G; Ke B; Ma G; Liu GL; Liang H; Liu LR; Hao XS
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1665-1671. PubMed ID: 29630110
[TBL] [Abstract][Full Text] [Related]
15. Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma.
Alafate W; Zuo J; Deng Z; Guo X; Wu W; Zhang W; Xie W; Wang M; Wang J
Pathol Res Pract; 2019 Oct; 215(10):152557. PubMed ID: 31353228
[TBL] [Abstract][Full Text] [Related]
16. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.
Loussouarn D; Campion L; Leclair F; Campone M; Charbonnel C; Ricolleau G; Gouraud W; Bataille R; Jézéquel P
Br J Cancer; 2009 Jul; 101(1):166-73. PubMed ID: 19513072
[TBL] [Abstract][Full Text] [Related]
17. Involvement of ubiquitin-conjugating enzyme E2C in proliferation and invasion of prostate carcinoma cells.
Shuliang S; Lei C; Guangwu J; Changjie L
Oncol Res; 2013; 21(3):121-7. PubMed ID: 24512726
[TBL] [Abstract][Full Text] [Related]
18. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.
Ma S; Chen Q; Li X; Fu J; Zhao L
Sci Rep; 2023 Oct; 13(1):16899. PubMed ID: 37803076
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target.
Huang GZ; Chen ZQ; Wu J; Shao TR; Zou C; Ai YL; Lv XZ
J Immunol Res; 2021; 2021():9250207. PubMed ID: 34950739
[TBL] [Abstract][Full Text] [Related]
20. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
